Stockscreener 앱 받기
14.61
0.75%
-0.11
전일 마감가:
$14.72
열려 있는:
$14.56
하루 거래량:
829.52K
Relative Volume:
0.34
시가총액:
$1.61B
수익:
$59.61M
순이익/손실:
$-262.14M
주가수익비율:
-3.727
EPS:
-3.92
순현금흐름:
$-247.49M
1주 성능:
+12.30%
1개월 성능:
-14.61%
6개월 성능:
+66.97%
1년 성능:
+70.08%
1일 변동 폭
$14.21
$14.77
1주일 범위
$12.79
$15.02
52주 변동 폭
$6.99
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
14.61 | 1.61B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? - MSN
Learn to Evaluate (ARQT) using the Charts - news.stocktradersdaily.com
Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets - Seeking Alpha
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 - The Manila Times
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Is Breakeven Near? - simplywall.st
Arcutis Biotherapeutics Appoints New Chief Financial Officer - MSN
Arcutis Announces Chief Financial Officer Transition | ARQT Stoc - GuruFocus
Arcutis Biotherapeutics (ARQT) Announces CFO Transition - GuruFocus
Arcutis Biotherapeutics (ARQT) Announces Transition in CFO Role - GuruFocus
Arcutis Names New Chief Financial Officer - Contract Pharma
Arcutis CFO David Topper retires, Latha Vairavan steps in By Investing.com - Investing.com India
Arcutis Announces Chief Financial Officer Transition - BioSpace
Arcutis Biotherapeutics Names New Chief Financial Officer - marketscreener.com
Arcutis CFO David Topper retires, Latha Vairavan steps in - Investing.com Australia
Psoriasis Pipeline Analysis and Clinical Trials Assessment, - openPR.com
Arcutis at Needham Conference: Strategic Growth in Dermatology By Investing.com - Investing.com Canada
Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) - Seeking Alpha
Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? - MSN
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Strengthens Team with Strategic Stock Grants to 5 Key New Hires - Stock Titan
(ARQT) Trading Report - news.stocktradersdaily.com
Arcutis stock holds buy rating, $19 target amid patent case By Investing.com - Investing.com Australia
Arcutis Biotherapeutics director sells $151,236 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics director sells $151,236 in stock - Investing.com India
Recent Insider Transactions at Arcutis Biotherapeutics - TradingView
Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews - Benzinga
Arcutis stock holds buy rating, $19 target amid patent case - Investing.com
Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Shares Rise Amid Patent Lawsuit P - GuruFocus
Arcutis stock rises following litigation stay By Investing.com - Investing.com Canada
Arcutis and Padagis agree to stay patent litigation By Investing.com - Investing.com South Africa
Arcutis And Padagis Agree To Stay Patent Lawsuit - MarketScreener
Arcutis stock gains after pausing patent suit (ARQT:NASDAQ) - Seeking Alpha
Arcutis rises after halting patent dispute with Padagis - TradingView
Arcutis Agrees to Stay Patent Lawsuit Against Padagis - MarketScreener
Arcutis and Padagis Agree to Stay Patent Lawsuit - The Manila Times
Arcutis and Padagis agree to stay patent litigation - Investing.com
Strategic Win: Arcutis Secures Extended Patent Protection for ZORYVE Until 2037 - Stock Titan
Arcutis: An Agent of Patient-Centric Transformation - Technology Magazine
Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast - openPR.com
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):